Healthcare Guide · November 06, 2026

Insomnia That Won't Go Away: What Works Better, CBT-I or Sleeping Pills?

For chronic insomnia, the American College of Physicians recommends CBT-I as the initial treatment, with a strong recommendation. A 2015 meta-analysis found it shortened time to fall asleep by 19.03 minutes. Some sleeping pills carry an FDA boxed warning, and insomnia can overlap with sleep apnea, which our Rooti patch ($210 / $380) can screen for.

Many adults sleep badly for a few weeks and recover. For some, poor sleep settles in for months. The two main options are a structured talking-and-habits therapy called CBT-I and prescription sleeping pills. The guidelines rank them differently.

How common is chronic insomnia?

A 2025 meta-analysis of 47 general-population studies in the Journal of Sleep Research found a pooled prevalence of insomnia disorder of 12.4% in studies that used a diagnostic interview based on DSM criteria. Studies using self-report questions based on DSM criteria gave 16.3%. Questionnaire-based studies ranged from 7.5% to 32.3%. The authors note that the numbers depend heavily on how insomnia is defined and measured.

"Chronic insomnia disorder" has a specific meaning: trouble falling asleep, staying asleep or waking too early, with daytime effects, happening often and for months rather than days. A doctor makes that diagnosis, not a quiz.

What is CBT-I, and what do the guidelines say about it?

CBT-I stands for cognitive behavioral therapy for insomnia. It is a short, structured program, usually delivered by a trained clinician, that targets the habits and thoughts that keep insomnia going. The parts commonly include limiting time in bed, keeping a regular wake time, linking the bed with sleep, and changing unhelpful beliefs about sleep.

American College of Physicians (2016): recommends that all adult patients receive CBT-I as the initial treatment for chronic insomnia disorder. The grade is "strong recommendation, moderate-quality evidence."
American Academy of Sleep Medicine (2021): recommends that clinicians use multicomponent CBT-I for adults with chronic insomnia disorder. This is also a strong recommendation.

How much does CBT-I actually help?

A 2015 meta-analysis in Annals of Internal Medicine pooled 20 studies with 1,162 participants who had chronic insomnia. After CBT-I:

Time to fall asleep improved by 19.03 minutes (95% CI, 14.12 to 23.93).
Time awake after first falling asleep improved by 26.00 minutes (95% CI, 15.48 to 36.52).
Sleep efficiency, the share of time in bed spent asleep, improved by 9.91% (95% CI, 8.09% to 11.73%).
Total sleep time improved by 7.61 minutes, but the confidence interval (-0.51 to 15.74) included zero, so that gain was not clearly different from no change.

In plain terms, CBT-I mostly helps people fall asleep faster and lie awake less. It does not reliably add much total sleep. That matters if you are measuring success by hours: the pooled gain shows up in how quickly sleep arrives and how few awake stretches break it, not in extra time asleep.

The meta-analysis describes its sample as 64% female with a mean age of 56. Results in much younger or older groups may differ.

What do the guidelines say about sleeping pills?

The 2016 ACP guideline gives medication a narrower role. It recommends a shared decision-making approach, including a discussion of the benefits, harms and costs of short-term use of medications, to decide whether to add a drug in adults in whom CBT-I alone was unsuccessful. That recommendation is graded "weak recommendation, low-quality evidence."

The 2017 AASM pharmacologic guideline reviewed individual drugs against no treatment, and every one of its recommendations was weak. It suggested for use zolpidem, eszopiclone and temazepam (sleep onset and sleep maintenance), suvorexant and doxepin (sleep maintenance), and zaleplon, triazolam and ramelteon (sleep onset). Among the drugs it suggested against for chronic insomnia were diphenhydramine, melatonin and trazodone.

What safety warning applies to some sleeping pills?

On April 30, 2019, the US FDA posted a Drug Safety Communication adding a boxed warning to three medicines: eszopiclone (Lunesta), zaleplon (Sonata) and zolpidem (Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist). The reason is complex sleep behaviors: sleepwalking, sleep driving and other activities while not fully awake, sometimes with no memory of them afterward. The FDA's advice for anyone who has such an episode includes contacting a health care professional right away.

CBT-I or sleeping pills: how do they compare?

	CBT-I	Sleeping pills
Guideline position	Initial treatment (ACP 2016, strong); multicomponent CBT-I recommended (AASM 2021, strong)	Considered if CBT-I alone did not work (ACP 2016, weak); drug-by-drug suggestions, all weak (AASM 2017)
What was measured	Falls asleep 19.03 minutes sooner; 26.00 minutes less awake after sleep onset; sleep efficiency up 9.91% (2015 meta-analysis)	ACP rates the evidence for adding medication as low quality
Safety note	No boxed warning	Eszopiclone, zaleplon and zolpidem carry an FDA boxed warning for complex sleep behaviors
Who delivers it	A trained clinician or a structured program, over several sessions	A prescriber

This is a guideline summary, not a prescription. If you take a sleep medicine now, do not change how you take it without your prescriber.

Could the insomnia be hiding sleep apnea?

Sometimes. An editorial in Brain Sciences (2021) on co-morbid insomnia and sleep apnea reports that 38% of people with obstructive sleep apnea meet the criteria for insomnia, and that 35% of insomnia patients have an Apnea-Hypopnea Index of 15 or more, which is moderate sleep apnea. Frequent awakenings, unrefreshing sleep and morning tiredness can come from either condition. Our guide to sleep apnea signs and testing covers the warning signs in detail.

Where does insomnia fit in a screening visit?

CBT-I and prescribing happen in a sleep or mental health clinic. What our health screening adds is a look for sleep apnea when your broken sleep comes with snoring, pauses in breathing or daytime sleepiness.

The Rooti 3 Day Sleep Study & Analysis is $210.
The Rooti 7 Day Sleep Study & Analysis is $380.
Both are done at iHope Clinic. You wear a waterproof chest ECG patch continuously for 3 or 7 days and nights. It records a single-lead ECG plus movement and position. The platform flags apnea events from the ECG signal, and arrhythmias such as atrial fibrillation.

Be clear about the limits. This is a multi-night screening study, not a polysomnogram, and it is not a diagnosis. A flagged result is a reason for a sleep specialist to look further. A clear result does not rule out every sleep disorder, and it says nothing about whether you have insomnia disorder.

This article is general education, not medical advice. Chronic insomnia, and any decision about sleep medicines, belongs with a doctor who knows your history.